Company intelligence / Profile preview
Catalyst Pharmaceuticals
- Ownership
- Public · CPRX
- Employees
- ~176
- Development stage
- Commercial
Overview
Catalyst Pharmaceuticals has three FDA-approved and commercialized products targeting rare neurological and neuromuscular diseases. Firdapse® is approved for LEMS in adults and children; Fycompa® treats partial-onset seizures in epilepsy; Agamree® was recently launched for Duchenne muscular dystrophy. The company continues to expand indications and dosing through supplemental approvals[3][9].
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecules (e.g., amifampridine, perampanel)Steroidal anti-inflammatory (vamorolone)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Catalyst Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Catalyst Pharmaceuticals.